Speiser W, Mallek R, Koppensteiner R, Stümpflen A, Kapiotis S, Minar E, Ehringer H, Lechner K
First Department of Medicine, University of Vienna, Austria.
Thromb Haemost. 1990 Oct 22;64(2):196-201.
The plasma levels of thrombin-antithrombin III-complexes (TAT) and the fibrin split product D-Dimer were measured in 39 patients with phlebographically proven acute DVT: 34 patients had proximal DVT, 5 had calf DVT. The sensitivity of D-Dimer and TAT measurements in the diagnosis of proximal DVT was found to be dependent on the duration of symptoms: 0 to 7 days (n = 27): elevated D-Dimer levels (greater than 120 ng/ml) = 1, D-Dimer Latex test positive (greater than 500 ng/ml) = 1, elevated TAT levels (greater than 6 ng/ml) = 0.88. Eight to 14 days (n = 7): elevated D-Dimer levels = 1, D-Dimer Latex test positive = 0.33, elevated TAT levels = 0.66; specificity: elevated D-Dimer: 0.48, D-Dimer Latex test: 1, elevated TAT: 0.76. Calf DVT patients (n = 5) had elevated D-Dimer levels, negative Latex tests and 3 of them had normal TAT values. Hemostatic and fibrinolytic parameters were also determined in 13 patients during heparin treatment of proximal DVT. Elevated D-Dimer and TAT levels rapidly decreased after initiation of anticoagulant therapy. In 2 of 13 patients a marked increase in D-Dimer and TAT levels was observed in periods of ineffective heparinization, documented by normal or only slightly prolonged thrombin clotting times. We conclude from our results that 1) D-Dimer EIA measurement, in contrast to TAT measurement, shows a very high sensitivity in the diagnosis of DVT, 2) due to low specificity this test can only be used to exclude thrombosis in patients with suspected DVT, and 3) the determination of the plasma levels of D-Dimer and TAT may be useful for judging the effect of anticoagulant treatment on thrombotic processes.
对39例经静脉造影证实为急性深静脉血栓形成(DVT)的患者测定了凝血酶 - 抗凝血酶III复合物(TAT)和纤维蛋白降解产物D - 二聚体的血浆水平:34例患者为近端DVT,5例为小腿DVT。发现D - 二聚体和TAT测定对近端DVT诊断的敏感性取决于症状持续时间:0至7天(n = 27):D - 二聚体水平升高(大于120 ng/ml)= 1例,D - 二聚体乳胶试验阳性(大于500 ng/ml)= 1例,TAT水平升高(大于6 ng/ml)= 0.88例。8至14天(n = 7):D - 二聚体水平升高= 1例,D - 二聚体乳胶试验阳性= 0.33例,TAT水平升高= 0.66例;特异性:D - 二聚体水平升高:0.48,D - 二聚体乳胶试验:1,TAT水平升高:0.76。小腿DVT患者(n = 5)D - 二聚体水平升高,乳胶试验阴性,其中3例TAT值正常。还对13例近端DVT患者在肝素治疗期间的止血和纤溶参数进行了测定。抗凝治疗开始后,升高的D - 二聚体和TAT水平迅速下降。13例患者中有2例在肝素化无效期间观察到D - 二聚体和TAT水平显著升高,凝血酶凝血时间正常或仅略有延长可证明这一点。我们从结果中得出结论:1)与TAT测定相比,D - 二聚体酶免疫分析测定在DVT诊断中显示出非常高的敏感性,2)由于特异性低,该试验仅可用于排除疑似DVT患者的血栓形成,3)测定血浆D - 二聚体和TAT水平可能有助于判断抗凝治疗对血栓形成过程的效果。